الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
This study aimed at evaluating the changes in the serum levels of vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGFβ1); the main angiogenic factors involved in hepatocarcinogenesis in cirrhotic patients who achieved the sustained virologic response (SVR) after direct acting antiviral agents (DAAs) therapy. In this prospective cohort study, 45 cirrhotic patients were recruited from National Liver Institute, Menoufia University, Egypt between September 2018 and February 2019 who received 60 mg oral daclatasvir and 400 mg oral sofosbuvir once daily for 12 weeks with or without ribavirin. Serum levels of VEGF and TGFβ1 were determined at baseline and 12 weeks after DAAs treatment. Our results demonstrated that, DAA-induced SVR didn’t significantly affect VEGF and TGFβ1 serum levels; the two critical players in hepatocarcinogenesis. We concluded that, DAAs are safe and lack the angiogenic and oncogenic potential. However, large scale prospective cohort studies with more extended follow-up period are still recommended.